Abstract
Atherosclerosis (AS) and arterial infarction currently have a significant impact on human health. Due to their complex pathogenesis and lack of effective treatment approaches, patients worldwide experience high mortality rates. Methyltransferase-like 3 (METTL3)-mediated RNA N(6)-modification has garnered considerable attention in elucidating the mechanisms underlying the pathogenesis and treatment failure of AS and arterial infarction. However, few reviews have explored the interrelationship between them. Therefore, this review aims to address this literature gap by evaluating all studies reporting on the involvement of METTL3 in AS and arterial infarction, as well as targeting METTL3 for rescuing these diseases. This review suggests that METTL3 serves as a risk factor, diagnostic biomarker and therapeutic target for AS and arterial infarction. Overall, it provides a comprehensive overview of cutting-edge research on METTL3 in AS and arterial infarction, serving as a convenient reference for researchers in both basic and translational medicine fields.